<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xml:lang="en" article-type="editorial" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">touchREV Endocrinol</journal-id><journal-id journal-id-type="iso-abbrev">touchREV Endocrinol</journal-id><journal-id journal-id-type="pmc-domain-id">4035</journal-id><journal-id journal-id-type="pmc-domain">touchrevendo</journal-id><journal-id journal-id-type="publisher-id">EE</journal-id><journal-title-group><journal-title>touchREVIEWS in Endocrinology</journal-title></journal-title-group><issn pub-type="epub">2752-5457</issn><publisher><publisher-name>Touch Medical Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11548364</article-id><article-id pub-id-type="pmcid-ver">PMC11548364.1</article-id><article-id pub-id-type="pmcaid">11548364</article-id><article-id pub-id-type="pmcaiid">11548364</article-id><article-id pub-id-type="pmid">39526050</article-id><article-id pub-id-type="doi">10.17925/EE.2024.20.2.3</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pituitary Disorders</subject></subj-group></article-categories><title-group><article-title>New Trends in Treating Cushing’s Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Violetis</surname><given-names initials="O">Odysseas</given-names></name></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Alexandraki</surname><given-names initials="KI">Krystallenia I</given-names></name></contrib></contrib-group><aff>
<addr-line>2nd Department of Surgery, Aretaieio Hospital, National and Kapodistrian University of Athens, Athens, Greece</addr-line>
</aff><author-notes><corresp><bold>Corresponding author</bold>: Dr Krystallenia I Alexandraki, 2nd Department of Surgery, Aretaieion Hospital, National and Kapodistrian University of Athens, 132 Kifisias Avenue, PC 15125, Athens, Marousi, Greece. E: <email>alexandrakik@gmail.com</email>
</corresp><fn id="FN1" fn-type="COI-statement"><p><bold>Disclosures</bold>: Odysseas Violetis and Krystallenia I Alexandraki have no financial or non-financial relationships or activities to declare in relation to this article.</p></fn></author-notes><pub-date pub-type="ppub"><month>10</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>08</day><month>4</month><year>2024</year></pub-date><volume>20</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">474686</issue-id><fpage>10</fpage><lpage>15</lpage><history><date date-type="received"><day>04</day><month>8</month><year>2023</year></date><date date-type="accepted"><day>17</day><month>10</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>10</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>09</day><month>11</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-11-21 01:25:16.700"><day>21</day><month>11</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>© Touch Medical Media 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Touch Medical Media 2024</copyright-holder><license><license-p>ali:free_to_read</license-p></license><license><license-p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.copyright.com">www.copyright.com</ext-link>
</license-p><license-p><bold>Review process</bold>: Double-blind peer review.</license-p><license-p><bold>Compliance with ethics</bold>: This article is an opinion piece and does not report on new clinical data, or any studies with human or animal subjects performed by any of the authors.</license-p><license-p><bold>Data availability</bold>: Data sharing is not applicable to this article as no datasets were generated or analyzed during the writing of this article.</license-p><license-p><bold>Authorship</bold>: The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.</license-p></license><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/3.0/</ali:license_ref><license-p><bold>Access</bold>: This article is freely accessible at touchENDOCRINOLOGY.com © Touch Medical Media 2024.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="touchendo-20-2-010.pdf"/><abstract><p>Rates of recurrence and/or persistence of Cushing’s disease after surgical treatment are high. Recently, advances in molecular insights and a better understanding of pathophysiology have enabled the development of potential therapeutic targets that could control adrenocorticotropic hormone (ACTH) and cortisol secretion or even reduce tumour cell proliferation. At the pituitary level, pasireotide is an approved somatostatin receptor ligand, and compounds targeting cell cycle regulation, cell signalling and epigenetics are now under investigation. Levoketoconazole and osilodrostat are novel steroid inhibitors, and relacorilant overcomes the adverse effects of mifepristone. Adrenal ACTH receptor blockage and immunotherapy could also play a role.</p></abstract><kwd-group><title>Keywords</title><kwd>Cushing’s disease</kwd><kwd>immunotherapy</kwd><kwd>levoketoconazole</kwd><kwd>novel drugs</kwd><kwd>osilodrostat</kwd><kwd>pasireotide</kwd><kwd>relacorilant</kwd></kwd-group><funding-group><funding-statement><bold>Support</bold>: No funding was received in the publication of this article.</funding-statement></funding-group><counts><page-count count="6"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Cushing’s disease (CD) is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma, or rarely carcinoma, and is considered a highly morbid endocrine disorder with few medical options.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> Although transsphenoidal pituitary surgery (TSS) is the mainstay of treatment for this disease, up to one-third of the patients eventually relapse and are required to be treated with a variety of drugs, as none can achieve optimal disease control.<sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref></sup> Drugs may aim directly at the corticotroph adenoma (pasireotide and cabergoline), act on the adrenal steroidogenesis pathway mitigating the cortisol synthesis (such as ketoconazole, etomidate, metyrapone and mitotane) or block the glucocorticoid receptor (mifepristone). Even though the first category of drugs is deemed more rational as they act directly on the pituitary tumour, targeting the source of ACTH secretion aiming to control or shrink the tumour, 60–75% of patients are insensitive to current pituitary-targeted agents.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> Furthermore, use of classic adrenal-directed drugs can achieve control of hypercortisolism in more than half of patients, but may induce severe adverse effects.<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup> Specifically, hepatotoxicity is a major issue in treatment with ketoconazole, while hirsutism and hypertension are associated with metyrapone. Therefore, developing new drugs that are well tolerated and effective in stabilizing the disease is considered pivotal.<sup><xref rid="R8" ref-type="bibr">8</xref></sup></p><p>Although ACTH-secreting tumours express somatostatin receptor 2 (SSTR2) and SSTR5 messenger RNAs (mRNAs) (&gt;85%) and, to a lesser degree, SSTR1 mRNA (63%), in the membrane, SSTR5 is predominant.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> Although the precise mechanism remains unclear, it seems glucocorticoids downregulate SSTR2, leaving SSTR5 intact, explaining the lack of efficacy of traditional SSTR2-targeting analogues in patients with CD.<sup><xref rid="R10" ref-type="bibr">10</xref>–<xref rid="R12" ref-type="bibr">12</xref></sup> Pasireotide is a novel somatostatin analogue targeting four out of five SSTR subtypes, with the highest affinity for SSTR5.<sup><xref rid="R3" ref-type="bibr">3</xref>–<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup> The first randomized phase III clinical trial (Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00434148">NCT00434148</ext-link>) involving 162 patients with CD treated with subcutaneous pasireotide showed urine-free cortisol (UFC) normalization at month 6 in 15–26% of the patients without uptitration, and, simultaneously, a significant clinical improvement was noted in most patients.<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup> However, it seems that pasireotide was more efficacious in cases with mild hypercortisolism. The response was rather rapid and sustained over a longer period, allowing the possibility of predicting how patients will respond to treatment early after the treatment initiation. Subsequent sustained improvement in blood pressure and lipid profile, as well as in quality of life and visceral adiposity, was noted during the long-term treatment with pasireotide.<sup><xref rid="R15" ref-type="bibr">15</xref></sup> Notably, adiposity and blood pressure were ameliorated, even if complete biochemical control was not achieved.<sup><xref rid="R16" ref-type="bibr">16</xref></sup> Similarly, tumour shrinkage was noticed irrespective of UFC reduction, distinguishing the action of pasireotide on tumour size and the inhibition of secretion.<sup><xref rid="R17" ref-type="bibr">17</xref></sup> To avoid subcutaneous pasireotide administration twice daily, a long-acting release formulation was developed and confirmed to have similar efficacy and safety to the short-acting form.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> Despite the benefits of pasireotide, about two-thirds of the patients developed hyperglycaemia-related adverse events, requiring additional antidiabetic treatment.<sup><xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref></sup></p><p>Several centrally acting agents are in development (<xref rid="F1" ref-type="fig">Figure 1</xref>, <xref rid="tab1" ref-type="table">Table 1</xref>).<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R19" ref-type="bibr">19</xref>–<xref rid="R28" ref-type="bibr">28</xref></sup> First, by binding to the retinoic acid receptor and retinoid X receptor, retinoid acid modulates proopiomelanocortin (POMC) expression, and studies on AtT20 mice pituitary ACTH-secreting tumour cells and animal models have shown that it can effectively suppress ACTH secretion and adenoma growth.<sup><xref rid="R29" ref-type="bibr">29</xref></sup> In two prospective studies on patients with CD, retinoic acid achieved UFC normalization and clinical improvement in a significant proportion of patients with mild hypercortisolism. Regarding its safety, the most common adverse effects were transient conjunctival irritation, cheilitis, mucositis, nausea, headache and arthralgias.<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref></sup></p><table-wrap position="float" id="tab1" orientation="portrait"><label>Table 1:</label><caption><title>Drugs for the management of Cushing's disease tested in clinical studies<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R19" ref-type="bibr">19</xref>–<xref rid="R28" ref-type="bibr">28</xref></sup></title></caption><table frame="hsides" rules="rows"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Drug name</th><th align="left" valign="top" rowspan="1" colspan="1">N</th><th align="left" valign="top" rowspan="1" colspan="1">Duration</th><th align="left" valign="top" rowspan="1" colspan="1">Effectiveness</th><th align="left" valign="top" rowspan="1" colspan="1">Side effects</th><th align="left" valign="top" rowspan="1" colspan="1">Clinical trial (phase, ClinicalTrials.gov identifier)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="5" colspan="1">Levoketoconazole</td><td align="left" valign="top" rowspan="2" colspan="1">94 (80 CD)</td><td align="left" valign="top" rowspan="5" colspan="1">Dose-titration period (2–21 weeks) and a 6 month maintenance period</td><td align="left" valign="top" rowspan="1" colspan="1">29/94 (31%) UFC normalization without dose increase.</td><td align="left" valign="top" rowspan="5" colspan="1">Gastrointestinal disturbances, headache, edema, liver enzyme increase , adrenal insufficiency</td><td align="left" valign="top" rowspan="2" colspan="1">SONICS (phase III; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01838551">NCT01838551</ext-link>)<sup><xref rid="R19" ref-type="bibr">19</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">34/55 (62%) and 9/55 (16%) had a complete and a partial response irrespective of dose increase (at the end of the core study), respectively</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">84 (70 CD)</td><td align="left" valign="top" rowspan="3" colspan="1">Open-l abel titration-maintenance (14–19 weeks) followed by double-blind, randomized-withdrawal (~8 weeks) and restoration (~8 weeks) phases</td><td align="left" valign="top" rowspan="1" colspan="1">72.2 % (57/79) achieved a complete or a partial response (at the end of titration-maintenance period).</td><td align="left" valign="top" rowspan="3" colspan="1">LOGICS (phase III; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03277690">NCT03277690</ext-link>)<sup><xref rid="R20" ref-type="bibr">20</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Normalization of mUFC in 50.0% patients in the levoketoconazole group versus 4.5 % in the placebo group (at the end of the randomization phase).</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Loss of mUFC response was significantly higher in the placebo group compared to levoketoconazole group (40.9% versus 95.5 %)</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Osilodrostat</td><td align="left" valign="top" rowspan="1" colspan="1">137 CD</td><td align="left" valign="top" rowspan="1" colspan="1">48 weeks (four phases)</td><td align="left" valign="top" rowspan="1" colspan="1">66 % had a complete response and 9 % had a partial response at the end of the core study (week 48)</td><td align="left" valign="top" rowspan="2" colspan="1">Fatigue, nausea, headache, diarrhea, adrenal insufficiency hypertension, hypokalaemia, QT-interval and in females hirsutism and acne</td><td align="left" valign="top" rowspan="1" colspan="1">LINC3 (phase III; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02180217">NCT02180217</ext-link>)<sup><xref rid="R21" ref-type="bibr">21</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">73 CD</td><td align="left" valign="top" rowspan="1" colspan="1">48 weeks (12 week, randomized, double-blind, placebo-controlled period and a 36 week, open-label period)</td><td align="left" valign="top" rowspan="1" colspan="1">68.5 % had a complete response and 11.0 % had a partial response at the end of the core study (week 48)</td><td align="left" valign="top" rowspan="1" colspan="1">LINC4 (phase III; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02697734">NCT02697734</ext-link>)<sup><xref rid="R22" ref-type="bibr">22</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Relacorilant</td><td align="left" valign="top" rowspan="2" colspan="1">35 (23 CD)</td><td align="left" valign="top" rowspan="2" colspan="1">20 weeks (up-titration period of 12–16 weeks and a 4 week, open-l abel, stable-dose period)</td><td align="left" valign="top" rowspan="1" colspan="1">In the low dose group, 42% and 15% demonstrated a BP reduction of ≥5 mmHg and a glycaemic reduction respectively.</td><td align="left" valign="top" rowspan="2" colspan="1">Back pain, headache, oedema, nausea, pain at extremities, diarrhea and dizziness</td><td align="left" valign="top" rowspan="2" colspan="1">Phase II study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02804750">NCT02804750</ext-link>)<sup><xref rid="R23" ref-type="bibr">23</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">In the high dose group, 64% and 50% demonstrated a BP reduction of ≥5 mmHg and a glycaemic reduction respectively</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pasireotide</td><td align="left" valign="top" rowspan="1" colspan="1">162 CD</td><td align="left" valign="top" rowspan="1" colspan="1">12 months</td><td align="left" valign="top" rowspan="1" colspan="1">Complete response in 15% and 26% and partial response in 18% and 13% in low and high dose group respectively (month 6)</td><td align="left" valign="top" rowspan="2" colspan="1">Diarrhea, cholelithiasis, hyperglycaemia, fatigue, abdominal pain, nausea</td><td align="left" valign="top" rowspan="1" colspan="1">Phase III study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00434148">NCT00434148</ext-link>)<sup><xref rid="R13" ref-type="bibr">13</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pasireotide LAR</td><td align="left" valign="top" rowspan="1" colspan="1">150 CD</td><td align="left" valign="top" rowspan="1" colspan="1">12 months</td><td align="left" valign="top" rowspan="1" colspan="1">Complete response in 41.9% and 40.8% and partial response in 5% and 13% in low and high group respectively (month 7)</td><td align="left" valign="top" rowspan="1" colspan="1">Phase III trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01374906">NCT01374906</ext-link>)<sup><xref rid="R24" ref-type="bibr">24</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Roscovitine(seliciclib)</td><td align="left" valign="top" rowspan="2" colspan="1">9 CD</td><td align="left" valign="top" rowspan="2" colspan="1">4 weeks</td><td align="left" valign="top" rowspan="2" colspan="1">5 patients had near or &gt;50% UFC reduction. None achieved normalization</td><td align="left" valign="top" rowspan="2" colspan="1">Transient elevated liver enzymes, anemia and elevated creatinine levels</td><td align="left" valign="top" rowspan="1" colspan="1">Phase II (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02160730">NCT02160730</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03774446">NCT03774446</ext-link>)<sup><xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tretinoin</td><td align="left" valign="top" rowspan="1" colspan="1">7 CD</td><td align="left" valign="top" rowspan="1" colspan="1">12 months</td><td align="left" valign="top" rowspan="1" colspan="1">3 patients had normalization or &gt;50% UFC reduction (month 12)</td><td align="left" valign="top" rowspan="1" colspan="1">Conjunctival irritation, nausea, headache and arthralgia</td><td align="left" valign="top" rowspan="1" colspan="1">Prospective, multicenter study<sup><xref rid="R27" ref-type="bibr">27</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Isotretinoin</td><td align="left" valign="top" rowspan="1" colspan="1">16 CD</td><td align="left" valign="top" rowspan="1" colspan="1">12 months</td><td align="left" valign="top" rowspan="1" colspan="1">4 patients had UFC normalization (month 12)</td><td align="left" valign="top" rowspan="1" colspan="1">Conjunctival irritation, cheilitis, mucositis, nausea, headache, and arthralgias</td><td align="left" valign="top" rowspan="1" colspan="1">Prospective open trial<sup><xref rid="R28" ref-type="bibr">28</xref></sup></td></tr></tbody></table><table-wrap-foot><p>
<italic toggle="yes">Complete response: UFC normalization; partial response: ≥50% UFC reduction.</italic>
</p><p>
<italic toggle="yes">BP = blood pressure; CD = Cushing's disease; LAR = long-acting release; mUFC = mean urinary free cortisol; UFC = urinary free cortisol.</italic>
</p></table-wrap-foot></table-wrap><fig position="float" id="F1" orientation="portrait"><label>Figure 1:</label><caption><title>The main mechanism of action of the novel drugs for Cushing’s disease</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="touchendo-20-2-010-g001.jpg"/><p><italic toggle="yes">Approved drugs are given in bold, drugs tested in humans but not approved are given in non-bold and drugs tested only</italic> in vitro <italic toggle="yes">or</italic>
<italic toggle="yes">in vivo in animals are given in italics. Graphical images of human body parts and molecules were sourced at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://smart.servier.com" ext-link-type="uri">https://smart.servier.com</ext-link>, which are available under a CC BY 4.0 International license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by/4.0/" ext-link-type="uri">https://creativecommons.org/licenses/by/4.0/</ext-link>).</italic></p><p>
<italic toggle="yes">BRAF = B-raf proto-oncogene, serine/threonine kinase; CDK = cyclin-dependent kinase; CTLA4 = cytotoxic T-lymphocyte associated protein 4; EGFR = epidermal growth factor receptor; HDAC = histone deacetylase; HSP90 = heat shock protein 90; MCR2 = melanocortin 2 receptor; PD-1 = programmed death-1; RAR = retinoic acid receptor; RXR = retinoid X receptor; SSTR = somatostatin receptor; USP8 = ubiquitin specific peptidase 8, RA-9: (3E,5E)-3,5-Bis[(4-Nitrophenyl)methylene]-4-piperidinone.</italic>
</p></fig><p>More than half of pituitary tumours, including corticotroph adenomas, express epidermal growth factor receptor (EGFR), which plays a key role in POMC expression. Interestingly, 36–62% of corticotroph adenomas show gain-of-function mutations in the gene encoding for <italic toggle="yes">USP8</italic>.<sup><xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R31" ref-type="bibr">31</xref></sup> This gene codes for a protein with deubiquitinase activity, which rescues proteins such as EGFR from lysosomal degradation. Mutated <italic toggle="yes">USP8</italic> exerts higher deubiquitinase activity, probably explaining the aberrant EGFR signalling in corticotrophs.<sup><xref rid="R31" ref-type="bibr">31</xref></sup> To date, two EGFR tyrosine kinase inhibitors, gefitinib and lapatinib, have been evaluated for the treatment of pituitary tumours.<sup><xref rid="R32" ref-type="bibr">32</xref></sup>
<italic toggle="yes">In vitro</italic> and <italic toggle="yes">in vivo</italic> studies have shown that both could significantly decrease POMC and ACTH productionm as well as reduce proliferation activity and tumour size.<sup><xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R34" ref-type="bibr">34</xref></sup> An ongoing clinical trial is evaluating gefitinib in patients with <italic toggle="yes">USP8</italic>-mutated CD, but no results released till now (Targeted therapy with gefitinib in patients with USP8-mutated Cushing's disease; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02484755">NCT02484755</ext-link>).<sup><xref rid="R35" ref-type="bibr">35</xref></sup> It is estimated that 16.5% of <italic toggle="yes">USP8</italic> wild-type corticotroph adenomas carry <italic toggle="yes">BRAF</italic> (B-raf proto-oncogene, serine/threonine kinase) mutations encoding <italic toggle="yes">p.V600E</italic>, resulting in increased MAPK (mitogen-activated protein kinase) activity and subsequent POMC expression. A BRAF-kinase inhibitor, vemurafenib, was reasonably evaluated, and it was discovered to suppress ACTH secretion from primary cultures of human corticotroph adenomas harbouring <italic toggle="yes">BRAF V600E</italic>.<sup><xref rid="R36" ref-type="bibr">36</xref></sup> Apparently, except for tyrosine kinase inhibitors, specific <italic toggle="yes">USP8</italic> inhibitors are being studied. Of note, POMC may be subject to ubiquitination, independent of <italic toggle="yes">USP8</italic> sequence status, thereby indicating the use of <italic toggle="yes">USP8</italic> inhibitors regardless of <italic toggle="yes">USP8</italic> mutation.<sup><xref rid="R37" ref-type="bibr">37</xref></sup> Reduced ACTH secretion and cell proliferation and increased apoptosis were noted with 9-ehtyloxyimino-9H-i ndeno[1,2-b] pyrazine-2,3dicarbonitrile and RA-9 9 ([3E,5E]-3,5-Bis[(4-Nitrophenyl) methylene]-4-piperidinone) <italic toggle="yes">in vitro</italic>.<sup><xref rid="R38" ref-type="bibr">38</xref>,<xref rid="R39" ref-type="bibr">39</xref></sup></p><p>Furthermore, cyclin E is upregulated in corticotroph tumours, and the activation of the cyclin E-cyclin-dependent kinase 2 complex promotes G1-to-S cycle-phase advance and cell division in corticotroph pituitary cells, causing autonomous ACTH overproduction.<sup><xref rid="R40" ref-type="bibr">40</xref></sup> Recently, it has been suggested that roscovitine, an inhibitor of cyclin-dependent kinase 2 and cyclin E, may be an effective target medication in corticotroph tumours. In a phase II study on patients with CD (Treatment of Cushing's Disease With R-roscovitine, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02160730">NCT02160730</ext-link>; and Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03774446">NCT03774446</ext-link>), 400 mg twice daily of roscovitine was administered for 4 consecutive days each week for 4 weeks.<sup><xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> About 50% of the patients achieved a near or ≥50% reduction in UFC and, simultaneously, exhibited a slightly greater drop in circulating ACTH, advocating the pituitary-directed mechanism of action of roscovitine. Transiently elevated liver enzymes, anaemia and elevated creatinine levels were the most common adverse features.<sup><xref rid="R41" ref-type="bibr">41</xref></sup></p><p>Heat shock protein 90 (HSP90) is a chaperone protein that induces conformational changes in the glucocorticoid receptor, among others, and affects its transcriptional activity.<sup><xref rid="R42" ref-type="bibr">42</xref></sup> Corticotroph adenomas overexpress HSP90, resulting in increased binding to the glucocorticoid receptor, thereby inhibiting its translocation and subsequent DNA binding. Therefore, HSP90 plays a significant role in controlling POMC expression. Overexpression of HSP90 contributes to the partial resistance of tumour cells to glucocorticoids. For that reason, an HSP90 inhibitor may dissociate the glucocorticoid receptor from HSP90, increasing the negative feedback of glucocorticoids at the pituitary level and modulating ACTH secretion.<sup><xref rid="R43" ref-type="bibr">43</xref></sup> Silibinin is a C-terminal inhibitor of HSP90 that has been studied as a potential treatment for several malignancies, such as prostate cancer, breast cancer, hepatic cell cancer and lymphoblastic leukaemia, and has a sufficient safety profile.<sup><xref rid="R44" ref-type="bibr">44</xref>,<xref rid="R45" ref-type="bibr">45</xref></sup> It seems that silibinin inhibits POMC expression and ACTH production while enhancing dexamethasone-induced suppression <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> in xenografted mice.<sup><xref rid="R45" ref-type="bibr">45</xref></sup></p><p>Epigenetics is an emerging field of cancer research and drug investigation. That being said, histone deacetylase (HDAC) inhibitors are compounds with promising antineoplastic properties.<sup><xref rid="R46" ref-type="bibr">46</xref></sup> Generally, in cancer, acetylation of chromatin is disrupted, and HDAC inhibition might lead to increased expression of tumour suppressor genes and reduced expression of oncogenes. HDAC inhibitors have been shown to inhibit ACTH synthesis, block cell proliferation or modulate glucocorticoid signalling. Trichostatin A, vorinostat, romidepsin, tubastatin A and CUDC907 (fimeprinostat), a dual HDAC and phosphoinositide-3-kinase inhibitor, have shown promising results in experiments.<sup><xref rid="R47" ref-type="bibr">47</xref></sup></p><p>Next, researchers considered blocking the ACTH receptor in the adrenal glands, called melanocortin 2 receptor (MCR2). ALD1613 (Alder BioPharmaceuticals, now Lundbeck Seattle Biopharmaceuticals, Bothell, WA, USA) is a novel long-acting monoclonal antibody that neutralizes MCR2, reducing intracellular cyclic adenosine monophosphate (cAMP) <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> in rodents and cynomolgus monkeys. Interestingly, plasma cortisol levels remained low for long after the treatment discontinuation.<sup><xref rid="R48" ref-type="bibr">48</xref></sup> A clinical trial examining <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="CRN04894">CRN04894</ext-link>, an oral nonpeptide selective antagonist for ACTH acting at the MC2R, is underway (A study to evaluate the safety and PK of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="CRN04894">CRN04894</ext-link> for the treatment of Cushing's syndrome; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05804669">NCT05804669</ext-link>).<sup><xref rid="R49" ref-type="bibr">49</xref></sup> Preclinical data both in rats, in which osmotic pumps of continuous ACTH administration were implanted, and in pituitary corticotrope tumour (AtT-20)-bearing mice have demonstrated robust suppression of corticosterone after daily administration of the oral ACTH antagonist, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="CRN04894">CRN04894</ext-link>.<sup><xref rid="R50" ref-type="bibr">50</xref></sup></p><p>Evidence for immune checkpoint inhibitor (ICI) efficacy is emerging from studies on other cancers.<sup><xref rid="R51" ref-type="bibr">51</xref></sup> The presence of tumour-i nfiltrating lymphocytes and other mononuclear cells, the discovery of increased levels of programmed death ligand-1 (PD-L1) on the surface of functioning adenomas and the secondary hypophysitis caused by immunotherapy suggest the use of ICIs in the treatment of aggressive corticotroph adenomas and carcinomas resistant to conventional chemotherapies.<sup><xref rid="R52" ref-type="bibr">52</xref></sup> Although both combined therapy with ipilimumab (anti-CTLA4 [cytotoxic T-l ymphocyte associated protein 4]) and nivolumab (anti-PD-1), and monotherapy with pembrolizumab (anti-PD-1), have been described only in case reports, they appear to have a promising potential for treating refractory cases.<sup><xref rid="R53" ref-type="bibr">53</xref>,<xref rid="R54" ref-type="bibr">54</xref></sup> Results from the two registered clinical trials (Nivolumab and ipilimumab in treating patients with rare tumors, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02834013">NCT02834013</ext-link>; and Nivolumab and ipilimumab in people with aggressive pituitary tumors; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04042753">NCT04042753</ext-link>) are anticipated to elucidate the efficacy of ICIs.<sup><xref rid="R53" ref-type="bibr">53</xref>–<xref rid="R56" ref-type="bibr">56</xref></sup></p><p>Contrary to the centrally active drugs that, in the majority, are in an experimental stage, steroidogenesis inhibitors show more concrete evidence that they can ameliorate hypercortisolism. Two prospective studies (Treatment for endogenous Cushing's syndrome [SONICS], <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01838551">NCT01838551</ext-link>; and A study to assess the safety and efficacy of levoketoconazole in the treatment of endogenous Cushing's syndrome [LOGICS], <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03277690">NCT03277690</ext-link>) examined levoketoconazole, a ketoconazole enantiomer (2S, 4R), as a possible therapy in patients with Cushing’s syndrome (including those with CD).<sup><xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R20" ref-type="bibr">20</xref></sup> Starting at a dose of 300 mg/day and titrated up to 1,200 mg/day, levoketoconazole normalized mean urinary free cortisol (mUFC) levels in more than 50% of the patients. Of note, in about 90% of patients with CD, tumour size stayed stable, while no new magnetic resonance imaging (MRI) findings were detected. An improvement in symptoms and comorbidities of Cushing’s syndrome after levoketoconazole treatment was seen, namely in body mass index (BMI), glucose metabolism, even in patients with diabetes mellitus, total cholesterol and low-density lipoprotein (LDL), quality of life, depressive status, peripheral oedema and hirsutism and acne in female patients. As anticipated, hypokalaemia and hypertension were frequent, while liver enzyme derangements and adrenal insufficiency were also reported.<sup><xref rid="R57" ref-type="bibr">57</xref>–<xref rid="R60" ref-type="bibr">60</xref></sup></p><p>Osilodrostat is a potent inhibitor of 11β-hydroxylase and aldosterone synthase, the enzymes responsible for the final step of cortisol and aldosterone biosynthesis, that showed promise as a potent steroid inhibitor based on a prospective double-blind phase III study (Safety and efficacy of LCI699 for the treatment of patients with Cushing's disease; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02180217">NCT02180217</ext-link> [LINC3]), including 137 patients with persistent or recurrent CD.<sup><xref rid="R21" ref-type="bibr">21</xref></sup> At the end of the core study (at week 48), osilodrostat resulted in a complete response in 66% and a partial response (≥50% reduction of UFC) in 9% of the enrolled patients, respectively. Clinical improvement was also noted by week 48 in body weight, blood pressure, fasting plasma glucose and lipid profile, as well as quality of life and depression status. With regard to tumour size, a similar percentage of patients had either a decrease or an increase of 20% or more in the adenoma (30% versus 29% at week 24 and 38% versus 33% at week 48, respectively), suggesting that osilodrostat did not adversely affect the tumour size.<sup><xref rid="R61" ref-type="bibr">61</xref></sup> Noteworthy, a long-term study suggested that up to week 72, osilodrostat succeeded in normalizing UFC in 81% of patients with sustained clinical improvement.<sup><xref rid="R62" ref-type="bibr">62</xref></sup> In the phase III multicentre trial LINC4 (Efficacy and safety evaluation of osilodrostat in Cushing's disease; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02697734">NCT02697734</ext-link>), at the end of randomization, osilodrostat achieved 77.1% UFC normalization versus 8% in the control group.<sup><xref rid="R22" ref-type="bibr">22</xref></sup> Blood pressure, lipid and glucose metabolism, adiposity, physical appearance and quality of life were also improved by week 12 and continued up to the end of the core study.<sup><xref rid="R63" ref-type="bibr">63</xref></sup> Regarding the safety profile, osilodrostat was generally well tolerated, but in females, hirsutism and acne were reported; hence, women should be monitored for symptoms of hyperandrogenism.<sup><xref rid="R64" ref-type="bibr">64</xref></sup></p><p>The non-selective steroid inhibition by mifepristone and its related adverse features resulted in the development of a highly selective, non-steroidal modulator of the glucocorticoid receptor called relacorilant.<sup><xref rid="R65" ref-type="bibr">65</xref></sup> Unlike mifepristone, relacorilant does not bind to the progesterone receptor, rendering patients free of progesterone receptor modulator-associated endometrial changes, namely endometrial thickening and vaginal bleeding.<sup><xref rid="R66" ref-type="bibr">66</xref></sup> A phase II study (Study to evaluate CORT125134 in participants with Cushing's syndrome; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02804750">NCT02804750</ext-link>) over 20 weeks showed that, after dose stabilization, 42% and 15% of the patients coming from the low-dose group (200 mg/day) demonstrated a blood pressure reduction of ≥5 mmHg and a glycaemic reduction, respectively, whereas in the high-dose group (400 mg/day), an improvement in hypertension and glucose metabolism was achieved in 64% and 50%, respectively.<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R67" ref-type="bibr">67</xref></sup> Two phase III clinical trials (A study of the efficacy and safety of relacorilant in patients with endogenous Cushing syndrome [GRACE], <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03697109">NCT03697109</ext-link>; and Efficacy and safety of relacorilant in patients with cortisol-secreting adrenal adenomas [GRADIENT] <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04308590">NCT04308590</ext-link>) testing relacorilant are underway.<sup><xref rid="R68" ref-type="bibr">68</xref>–<xref rid="R70" ref-type="bibr">70</xref></sup> Interestingly, it has been reported to induce tumour shrinkage in some patients with CD with pituitary macroadenomas. A hypothesis for this finding could be the increased sensitivity to endogenous somatostatin due to the upregulation of SSTR2 on the tumour surface, through which hypercortisolaemia downregulates. It remains to be formally elucidated by the ongoing trials.<sup><xref rid="R71" ref-type="bibr">71</xref>,<xref rid="R72" ref-type="bibr">72</xref></sup></p><p>The management of recurrent or persistent corticotroph adenoma requires an individualized approach by an experienced multidisciplinary team.<sup><xref rid="R73" ref-type="bibr">73</xref></sup> Repeat TSS has low remission rates, and radiation therapy has a slow onset of action and can cause severe complications, such as hypopituitarism.<sup><xref rid="R74" ref-type="bibr">74</xref></sup> Research on the pathogenesis of corticotroph adenomas has opened new avenues for discovering and developing new treatment options. Although <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> studies in xenograft mice have shown encouraging results, these compounds remain to be tested in clinical studies. Levoketoconazole and osilodrostat have been approved for controlling cortisol excess and comorbidities. The somatostatin analogue pasireotide is the only currently approved tumour-targeted therapy. It has already been proposed that ACTH-producing adenomas were categorized based on <italic toggle="yes">USP8</italic> mutations, emphasizing the importance of genetics in therapy.<sup><xref rid="R75" ref-type="bibr">75</xref></sup> Molecular classification could lead to a more personalized treatment in the future. The selection of the agent depends not only on individual patients’ and tumour characteristics, availability and cost, but also on highly specific molecular patterns.</p></body><back><ref-list><ref id="R1"><label>1.</label><element-citation publication-type="journal"><name name-style="western"><surname>Nieman</surname><given-names>LK</given-names></name><name name-style="western"><surname>Biller</surname><given-names>BMK</given-names></name><name name-style="western"><surname>Findling</surname><given-names>JW</given-names></name><etal/><article-title>Treatment of Cushing's syndrome: An Endocrine Society clinical practice guideline.</article-title><source>J Clin Endocrinol Metab.</source><year>2015</year><volume>100</volume><fpage>2807</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1210/jc.2015-1818</pub-id><pub-id pub-id-type="pmid">26222757</pub-id><pub-id pub-id-type="pmcid">PMC4525003</pub-id></element-citation></ref><ref id="R2"><label>2.</label><element-citation publication-type="journal"><name name-style="western"><surname>Alexandraki</surname><given-names>KI</given-names></name><name name-style="western"><surname>Grossman</surname><given-names>AB</given-names></name><article-title>Therapeutic strategies for the treatment of severe Cushing's syndrome.</article-title><source>Drugs.</source><year>2016</year><volume>76</volume><fpage>447</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1007/s40265-016-0539-6</pub-id><pub-id pub-id-type="pmid">26833215</pub-id></element-citation></ref><ref id="R3"><label>3.</label><element-citation publication-type="journal"><name name-style="western"><surname>Alexandraki</surname><given-names>KI</given-names></name><name name-style="western"><surname>Kaltsas</surname><given-names>GA</given-names></name><name name-style="western"><surname>Isidori</surname><given-names>AM</given-names></name><etal/><article-title>Long-term remission and recurrence rates in Cushing’s disease: Predictive factors in a single-centre study.</article-title><source>Eur J Endocrinol.</source><year>2013</year><volume>168</volume><fpage>639</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1530/EJE-12-0921</pub-id><pub-id pub-id-type="pmid">23371975</pub-id></element-citation></ref><ref id="R4"><label>4.</label><element-citation publication-type="journal"><name name-style="western"><surname>Roelfsema</surname><given-names>F</given-names></name><name name-style="western"><surname>Biermasz</surname><given-names>NR</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>AM</given-names></name><article-title>Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: A structured review and meta-analysis.</article-title><source>Pituitary.</source><year>2012</year><volume>15</volume><fpage>71</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1007/s11102-011-0347-7</pub-id><pub-id pub-id-type="pmid">21918830</pub-id><pub-id pub-id-type="pmcid">PMC3296023</pub-id></element-citation></ref><ref id="R5"><label>5.</label><element-citation publication-type="journal"><name name-style="western"><surname>Broersen</surname><given-names>LHA</given-names></name><name name-style="western"><surname>Jha</surname><given-names>M</given-names></name><name name-style="western"><surname>Biermasz</surname><given-names>NR</given-names></name><etal/><article-title>Effectiveness of medical treatment for Cushing’s syndrome: A systematic review and meta-analysis.</article-title><source>Pituitary.</source><year>2018</year><volume>21</volume><fpage>631</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1007/s11102-018-0897-z</pub-id><pub-id pub-id-type="pmid">29855779</pub-id><pub-id pub-id-type="pmcid">PMC6244780</pub-id></element-citation></ref><ref id="R6"><label>6.</label><element-citation publication-type="journal"><name name-style="western"><surname>Viecceli</surname><given-names>C</given-names></name><name name-style="western"><surname>Mattos</surname><given-names>ACV</given-names></name><name name-style="western"><surname>Hirakata</surname><given-names>VN</given-names></name><etal/><article-title>Ketoconazole as second-l ine treatment for Cushing's disease after rranssphenoidal surgery: Systematic review and meta-analysis.</article-title><source>Front Endocrinol (Lausanne).</source><year>2023</year><volume>14</volume><fpage>1145775</fpage><pub-id pub-id-type="doi">10.3389/fendo.2023.1145775</pub-id><pub-id pub-id-type="pmid">37223017</pub-id><pub-id pub-id-type="pmcid">PMC10200879</pub-id></element-citation></ref><ref id="R7"><label>7.</label><element-citation publication-type="journal"><name name-style="western"><surname>Daniel</surname><given-names>E</given-names></name><name name-style="western"><surname>Aylwin</surname><given-names>S</given-names></name><name name-style="western"><surname>Mustafa</surname><given-names>O</given-names></name><etal/><article-title>Effectiveness of metyrapone in treating Cushing's syndrome: A retrospective multicenter study in 195 patients.</article-title><source>J Clin Endocrinol Metab.</source><year>2015</year><volume>100</volume><fpage>4146</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1210/jc.2015-2616</pub-id><pub-id pub-id-type="pmid">26353009</pub-id><pub-id pub-id-type="pmcid">PMC5393433</pub-id></element-citation></ref><ref id="R8"><label>8.</label><element-citation publication-type="journal"><name name-style="western"><surname>Pivonello</surname><given-names>R</given-names></name><name name-style="western"><surname>Ferrigno</surname><given-names>R</given-names></name><name name-style="western"><surname>De Martino</surname><given-names>MC</given-names></name><etal/><article-title>Medical treatment of Cushing’s disease: An overview of the current and recent clinical trials.</article-title><source>Front Endocrinol.</source><year>2020</year><volume>11</volume><fpage>648</fpage><pub-id pub-id-type="doi">10.3389/fendo.2020.00648</pub-id><pub-id pub-id-type="pmcid">PMC7753248</pub-id><pub-id pub-id-type="pmid">33363514</pub-id></element-citation></ref><ref id="R9"><label>9.</label><element-citation publication-type="journal"><name name-style="western"><surname>Alexandraki</surname><given-names>KI</given-names></name><name name-style="western"><surname>Grossman</surname><given-names>AB</given-names></name><article-title>Medical therapy of Cushing's disease: Where are we now?</article-title><source>Front Horm Res.</source><year>2010</year><volume>38</volume><fpage>165</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1159/000318507</pub-id><pub-id pub-id-type="pmid">20616508</pub-id></element-citation></ref><ref id="R10"><label>10.</label><element-citation publication-type="journal"><name name-style="western"><surname>Nishioka</surname><given-names>H</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>S</given-names></name><article-title>Cushing’s disease.</article-title><source>J Clin Med.</source><year>2019</year><volume>8</volume><fpage>1951</fpage><pub-id pub-id-type="doi">10.3390/jcm8111951</pub-id><pub-id pub-id-type="pmid">31726770</pub-id><pub-id pub-id-type="pmcid">PMC6912360</pub-id></element-citation></ref><ref id="R11"><label>11.</label><element-citation publication-type="journal"><name name-style="western"><surname>der Hoek</surname><given-names>J van</given-names></name><name name-style="western"><surname>Lamberts</surname><given-names>SWJ</given-names></name><name name-style="western"><surname>Hofland</surname><given-names>LJ</given-names></name><article-title>The role of somatostatin analogs in Cushing’s disease.</article-title><source>Pituitary.</source><year>2004</year><volume>7</volume><fpage>257</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1007/s11102-005-1404-x</pub-id><pub-id pub-id-type="pmid">16132202</pub-id></element-citation></ref><ref id="R12"><label>12.</label><element-citation publication-type="journal"><name name-style="western"><surname>Stalla</surname><given-names>GK</given-names></name><name name-style="western"><surname>Brockmeier</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Renner</surname><given-names>U</given-names></name><etal/><article-title>Octreotide exerts different effects in vivo and in vitro in Cushing’s disease.</article-title><source>Eur J Endocrinol.</source><year>1994</year><volume>130</volume><fpage>125</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1530/eje.0.1300125</pub-id><pub-id pub-id-type="pmid">8130885</pub-id></element-citation></ref><ref id="R13"><label>13.</label><element-citation publication-type="other"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link><article-title>Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing’s Disease.</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link><comment>identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00434148">NCT00434148</ext-link>. 2016. Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT00434148" ext-link-type="uri">https://clinicaltrials.gov/study/NCT00434148</ext-link><comment>(Date last accessed: 13 February 2024)</comment></element-citation></ref><ref id="R14"><label>14.</label><element-citation publication-type="journal"><name name-style="western"><surname>Colao</surname><given-names>A</given-names></name><name name-style="western"><surname>Petersenn</surname><given-names>S</given-names></name><name name-style="western"><surname>Newell-Price</surname><given-names>J</given-names></name><etal/><article-title>A 12-month phase 3 study of pasireotide in Cushing’s disease.</article-title><source>N Engl J Med.</source><year>2012</year><volume>366</volume><fpage>914</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1105743</pub-id><pub-id pub-id-type="pmid">22397653</pub-id></element-citation></ref><ref id="R15"><label>15.</label><element-citation publication-type="journal"><name name-style="western"><surname>Petersenn</surname><given-names>S</given-names></name><name name-style="western"><surname>Salgado</surname><given-names>LR</given-names></name><name name-style="western"><surname>Schopohl</surname><given-names>J</given-names></name><etal/><article-title>Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-l abel extension study of a phase III trial.</article-title><source>Endocrine.</source><year>2017</year><volume>57</volume><fpage>156</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1007/s12020-017-1316-3</pub-id><pub-id pub-id-type="pmid">28597198</pub-id><pub-id pub-id-type="pmcid">PMC5486525</pub-id></element-citation></ref><ref id="R16"><label>16.</label><element-citation publication-type="journal"><name name-style="western"><surname>Pivonello</surname><given-names>R</given-names></name><name name-style="western"><surname>Petersenn</surname><given-names>S</given-names></name><name name-style="western"><surname>Newell-Price</surname><given-names>J</given-names></name><etal/><article-title>Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing’s disease: Results from a phase III study.</article-title><source>Clin Endocrinol (Oxf).</source><year>2014</year><volume>81</volume><fpage>408</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1111/cen.12431</pub-id><pub-id pub-id-type="pmid">24533697</pub-id></element-citation></ref><ref id="R17"><label>17.</label><element-citation publication-type="journal"><name name-style="western"><surname>Bolanowski</surname><given-names>M</given-names></name><name name-style="western"><surname>Kałużny</surname><given-names>M</given-names></name><name name-style="western"><surname>Witek</surname><given-names>P</given-names></name><name name-style="western"><surname>Jawiarczyk-Przybyłowska</surname><given-names>A</given-names></name><article-title>Pasireotide – A novel somatostatin receptor ligand after 20 years of use.</article-title><source>Rev Endocr Metab Disord.</source><year>2022</year><volume>23</volume><fpage>601</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1007/s11154-022-09710-3</pub-id><pub-id pub-id-type="pmid">35067849</pub-id><pub-id pub-id-type="pmcid">PMC9156514</pub-id></element-citation></ref><ref id="R18"><label>18.</label><element-citation publication-type="journal"><name name-style="western"><surname>Lacroix</surname><given-names>A</given-names></name><name name-style="western"><surname>Gu</surname><given-names>F</given-names></name><name name-style="western"><surname>Gallardo</surname><given-names>W</given-names></name><etal/><article-title>Efficacy and safety of once-monthly pasireotide in Cushing’s disease: A 12 month clinical trial.</article-title><source>Lancet Diabetes Endocrinol.</source><year>2018</year><volume>6</volume><fpage>17</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(17)30326-1</pub-id><pub-id pub-id-type="pmid">29032078</pub-id></element-citation></ref><ref id="R19"><label>19.</label><element-citation publication-type="other"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://Clinicaltrials.Gov" ext-link-type="uri">Clinicaltrials.Gov</ext-link><article-title>Treatment for Endogenous Cushing’s Syndrome (SONICS).</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link><comment>identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01838551">NCT01838551</ext-link>. 2021. Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT01838551" ext-link-type="uri">https://clinicaltrials.gov/study/NCT01838551</ext-link><comment>(Date last accessed: 4 April 2024)</comment></element-citation></ref><ref id="R20"><label>20.</label><element-citation publication-type="other"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://Clinicaltrials.Gov" ext-link-type="uri">Clinicaltrials.Gov</ext-link><article-title>A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome.</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link><comment>identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03277690">NCT03277690</ext-link>. 2022. Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT03277690" ext-link-type="uri">https://clinicaltrials.gov/study/NCT03277690</ext-link><comment>(Date last accessed: 4 April 2024)</comment></element-citation></ref><ref id="R21"><label>21.</label><element-citation publication-type="other"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://Clinicaltrials.Gov" ext-link-type="uri">Clinicaltrials.Gov</ext-link><article-title>Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing’s Disease.</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link><comment>identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02180217">NCT02180217</ext-link>. 2021. Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT02180217" ext-link-type="uri">https://clinicaltrials.gov/study/NCT02180217</ext-link><comment>(Date last accessed: 4 April 2024)</comment></element-citation></ref><ref id="R22"><label>22.</label><element-citation publication-type="other"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link><article-title>Efficacy and Safety Evaluation of Osilodrostat in Cushing’s Disease (LINC-4).</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link><comment>identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02697734">NCT02697734</ext-link>. 2021. Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://classic.clinicaltrials.gov/ct2/show/NCT02697734" ext-link-type="uri">https://classic.clinicaltrials.gov/ct2/show/NCT02697734</ext-link><comment>(Date last accessed: 4 April 2024)</comment></element-citation></ref><ref id="R23"><label>23.</label><element-citation publication-type="other"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://Clinicaltrials.Gov" ext-link-type="uri">Clinicaltrials.Gov</ext-link><article-title>Study to Evaluate CORT125134 in Participants With Cushing’s Syndrome.</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link><comment>identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02804750">NCT02804750</ext-link>. 2019. Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT02804750" ext-link-type="uri">https://clinicaltrials.gov/study/NCT02804750</ext-link><comment>(Date last accessed: 4 April 2024)</comment></element-citation></ref><ref id="R24"><label>24.</label><element-citation publication-type="other"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://Clinicaltrials.Gov" ext-link-type="uri">Clinicaltrials.Gov</ext-link><article-title>Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing’s Disease.</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link><comment>identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01374906">NCT01374906</ext-link>. 2018. Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.clinicaltrials.gov/study/NCT01374906" ext-link-type="uri">www.clinicaltrials.gov/study/NCT01374906</ext-link><comment>(Date last accessed: 4 April 2024)</comment></element-citation></ref><ref id="R25"><label>25.</label><element-citation publication-type="other"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://Clinicaltrials.Gov" ext-link-type="uri">Clinicaltrials.Gov</ext-link><article-title>Treatment of Cushing’s Disease With R-roscovitine.</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link><comment>identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02160730">NCT02160730</ext-link>. 2021. Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT02160730" ext-link-type="uri">https://clinicaltrials.gov/study/NCT02160730</ext-link><comment>(Date last accessed: 5 April 2024)</comment></element-citation></ref><ref id="R26"><label>26.</label><element-citation publication-type="other"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://Clinicaltrials.Gov" ext-link-type="uri">Clinicaltrials.Gov</ext-link><article-title>Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease.</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link><comment>identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03774446">NCT03774446</ext-link>. 2023. Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT03774446" ext-link-type="uri">https://clinicaltrials.gov/study/NCT03774446</ext-link><comment>(Date last accessed: 5 April 2024)</comment></element-citation></ref><ref id="R27"><label>27.</label><element-citation publication-type="journal"><name name-style="western"><surname>Pecori Giraldi</surname><given-names>F</given-names></name><name name-style="western"><surname>Ambrogio</surname><given-names>AG</given-names></name><name name-style="western"><surname>Andrioli</surname><given-names>M</given-names></name><etal/><article-title>Potential role for retinoic acid in patients with Cushing’s disease.</article-title><source>J Clin Endocrinol Metab.</source><year>2012</year><volume>97</volume><fpage>3577</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1210/jc.2012-2328</pub-id><pub-id pub-id-type="pmid">22851491</pub-id></element-citation></ref><ref id="R28"><label>28.</label><element-citation publication-type="journal"><name name-style="western"><surname>Vilar</surname><given-names>L</given-names></name><name name-style="western"><surname>Albuquerque</surname><given-names>JL</given-names></name><name name-style="western"><surname>Lyra</surname><given-names>R</given-names></name><etal/><article-title>The role of Isotretinoin therapy for Cushing’s disease: Results of a prospective study.</article-title><source>Int J Endocrinol.</source><year>2016</year><volume>2016</volume><fpage>8173182</fpage><pub-id pub-id-type="doi">10.1155/2016/8173182</pub-id><pub-id pub-id-type="pmid">27034666</pub-id><pub-id pub-id-type="pmcid">PMC4789464</pub-id></element-citation></ref><ref id="R29"><label>29.</label><element-citation publication-type="journal"><name name-style="western"><surname>Fuertes</surname><given-names>M</given-names></name><name name-style="western"><surname>Tkatch</surname><given-names>J</given-names></name><name name-style="western"><surname>Rosmino</surname><given-names>J</given-names></name><etal/><article-title>Insights in Cushing disease treatment with focus on a derivative of vitamin A.</article-title><source>Front Endocrinol (Lausanne).</source><year>2018</year><volume>9</volume><fpage>262</fpage><pub-id pub-id-type="doi">10.3389/fendo.2018.00262</pub-id><pub-id pub-id-type="pmid">29881371</pub-id><pub-id pub-id-type="pmcid">PMC5976796</pub-id></element-citation></ref><ref id="R30"><label>30.</label><element-citation publication-type="journal"><name name-style="western"><surname>Ma</surname><given-names>Z-Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>Z-J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J-H</given-names></name><etal/><article-title>Recurrent gain-of-function Usp8 mutations in Cushing’s disease.</article-title><source>Cell Res.</source><year>2015</year><volume>25</volume><fpage>306</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1038/cr.2015.20</pub-id><pub-id pub-id-type="pmid">25675982</pub-id><pub-id pub-id-type="pmcid">PMC4349249</pub-id></element-citation></ref><ref id="R31"><label>31.</label><element-citation publication-type="journal"><name name-style="western"><surname>Perez-Rivas</surname><given-names>LG</given-names></name><name name-style="western"><surname>Theodoropoulou</surname><given-names>M</given-names></name><name name-style="western"><surname>Ferraù</surname><given-names>F</given-names></name><etal/><article-title>The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing Cushing’s disease.</article-title><source>J Clin Endocrinol Metab.</source><year>2015</year><volume>100</volume><fpage>E997</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1210/jc.2015-1453</pub-id><pub-id pub-id-type="pmid">25942478</pub-id><pub-id pub-id-type="pmcid">PMC4490309</pub-id></element-citation></ref><ref id="R32"><label>32.</label><element-citation publication-type="journal"><name name-style="western"><surname>Ben-Shlomo</surname><given-names>A</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>O</given-names></name><article-title>Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: From bench to bedside.</article-title><source>Curr Opin Endocrinol Diabetes Obes.</source><year>2017</year><volume>24</volume><fpage>301</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1097/MED.0000000000000344</pub-id><pub-id pub-id-type="pmid">28520590</pub-id><pub-id pub-id-type="pmcid">PMC5815830</pub-id></element-citation></ref><ref id="R33"><label>33.</label><element-citation publication-type="journal"><name name-style="western"><surname>Fukuoka</surname><given-names>H</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>O</given-names></name><name name-style="western"><surname>Ben-Shlomo</surname><given-names>A</given-names></name><etal/><article-title>EGFR as a therapeutic target for human, canine, and Mouse ACTH-Secreting pituitary adenomas.</article-title><source>J Clin Invest.</source><year>2011</year><volume>121</volume><fpage>4712</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1172/JCI60417</pub-id><pub-id pub-id-type="pmid">22105169</pub-id><pub-id pub-id-type="pmcid">PMC3226010</pub-id></element-citation></ref><ref id="R34"><label>34.</label><element-citation publication-type="journal"><name name-style="western"><surname>Asari</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kageyama</surname><given-names>K</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>A</given-names></name><etal/><article-title>Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells.</article-title><source>Endocr J.</source><year>2019</year><volume>66</volume><fpage>515</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1507/endocrj.EJ18-0491</pub-id><pub-id pub-id-type="pmid">30880293</pub-id></element-citation></ref><ref id="R35"><label>35.</label><element-citation publication-type="other"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link><article-title>Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing’s Disease.</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link><comment>identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02484755">NCT02484755</ext-link>. 2015. Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT02484755" ext-link-type="uri">https://clinicaltrials.gov/study/NCT02484755</ext-link><comment>(Date last accessed: 13 February 2024)</comment></element-citation></ref><ref id="R36"><label>36.</label><element-citation publication-type="journal"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Jian</surname><given-names>X</given-names></name><name name-style="western"><surname>Deng</surname><given-names>S</given-names></name><etal/><article-title>Identification of recurrent Usp48 and BRAF mutations in Cushing’s disease.</article-title><source>Nat Commun.</source><year>2018</year><volume>9</volume><fpage>3171</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-05275-5</pub-id><pub-id pub-id-type="pmid">30093687</pub-id><pub-id pub-id-type="pmcid">PMC6085354</pub-id></element-citation></ref><ref id="R37"><label>37.</label><element-citation publication-type="journal"><name name-style="western"><surname>Sesta</surname><given-names>A</given-names></name><name name-style="western"><surname>Cassarino</surname><given-names>MF</given-names></name><name name-style="western"><surname>Terreni</surname><given-names>M</given-names></name><etal/><article-title>Ubiquitin-specific protease 8 mutant corticotrope adenomas present unique secretory and molecular features and shed light on the role of ubiquitylation on ACTH processing.</article-title><source>Neuroendocrinology.</source><year>2020</year><volume>110</volume><fpage>119</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1159/000500688</pub-id><pub-id pub-id-type="pmid">31280266</pub-id><pub-id pub-id-type="pmcid">PMC6979434</pub-id></element-citation></ref><ref id="R38"><label>38.</label><element-citation publication-type="journal"><name name-style="western"><surname>Treppiedi</surname><given-names>D</given-names></name><name name-style="western"><surname>Di Muro</surname><given-names>G</given-names></name><name name-style="western"><surname>Marra</surname><given-names>G</given-names></name><etal/><article-title>Usp8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs.</article-title><source>Endocr Relat Cancer.</source><year>2021</year><volume>28</volume><fpage>573</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1530/ERC-21-0093</pub-id><pub-id pub-id-type="pmid">34086599</pub-id></element-citation></ref><ref id="R39"><label>39.</label><element-citation publication-type="journal"><name name-style="western"><surname>Kageyama</surname><given-names>K</given-names></name><name name-style="western"><surname>Asari</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sugimoto</surname><given-names>Y</given-names></name><etal/><article-title>Ubiquitin-specific protease 8 inhibitor suppresses adrenocorticotropic hormone production and corticotroph tumor cell proliferation.</article-title><source>Endocr J.</source><year>2020</year><volume>67</volume><fpage>177</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1507/endocrj.EJ19-0239</pub-id><pub-id pub-id-type="pmid">31666445</pub-id></element-citation></ref><ref id="R40"><label>40.</label><element-citation publication-type="journal"><name name-style="western"><surname>Liu</surname><given-names>N-A</given-names></name><name name-style="western"><surname>Araki</surname><given-names>T</given-names></name><name name-style="western"><surname>Cuevas-Ramos</surname><given-names>D</given-names></name><etal/><article-title>Cyclin e-mediated human proopiomelanocortin regulation as a therapeutic target for Cushing disease.</article-title><source>J Clin Endocrinol Metab.</source><year>2015</year><volume>100</volume><fpage>2557</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1210/jc.2015-1606</pub-id><pub-id pub-id-type="pmid">25942479</pub-id><pub-id pub-id-type="pmcid">PMC5393529</pub-id></element-citation></ref><ref id="R41"><label>41.</label><element-citation publication-type="journal"><name name-style="western"><surname>Liu</surname><given-names>N-A</given-names></name><name name-style="western"><surname>Ben-Shlomo</surname><given-names>A</given-names></name><name name-style="western"><surname>Carmichael</surname><given-names>JD</given-names></name><etal/><article-title>Treatment of Cushing disease with pituitary-targeting Seliciclib.</article-title><source>J Clin Endocrinol Metab.</source><year>2023</year><volume>108</volume><fpage>726</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1210/clinem/dgac588</pub-id><pub-id pub-id-type="pmid">36214832</pub-id><pub-id pub-id-type="pmcid">PMC10210614</pub-id></element-citation></ref><ref id="R42"><label>42.</label><element-citation publication-type="journal"><name name-style="western"><surname>Kirschke</surname><given-names>E</given-names></name><name name-style="western"><surname>Goswami</surname><given-names>D</given-names></name><name name-style="western"><surname>Southworth</surname><given-names>D</given-names></name><etal/><article-title>Glucocorticoid receptor function regulated by coordinated action of the Hsp90 and Hsp70 chaperone cycles.</article-title><source>Cell.</source><year>2014</year><volume>157</volume><fpage>1685</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.04.038</pub-id><pub-id pub-id-type="pmid">24949977</pub-id><pub-id pub-id-type="pmcid">PMC4087167</pub-id></element-citation></ref><ref id="R43"><label>43.</label><element-citation publication-type="journal"><name name-style="western"><surname>Hinojosa-Amaya</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lam-Chung</surname><given-names>CE</given-names></name><name name-style="western"><surname>Cuevas-Ramos</surname><given-names>D</given-names></name><article-title>Recent understanding and future directions of recurrent corticotroph tumors.</article-title><source>Front Endocrinol (Lausanne).</source><year>2021</year><volume>12</volume><fpage>657382</fpage><pub-id pub-id-type="doi">10.3389/fendo.2021.657382</pub-id><pub-id pub-id-type="pmid">33986726</pub-id><pub-id pub-id-type="pmcid">PMC8111286</pub-id></element-citation></ref><ref id="R44"><label>44.</label><element-citation publication-type="journal"><name name-style="western"><surname>Deep</surname><given-names>G</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>R</given-names></name><article-title>Antimetastatic efficacy of silibinin: Molecular mechanisms and therapeutic potential against cancer.</article-title><source>Cancer Metastasis Rev.</source><year>2010</year><volume>29</volume><fpage>447</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1007/s10555-010-9237-0</pub-id><pub-id pub-id-type="pmid">20714788</pub-id><pub-id pub-id-type="pmcid">PMC3928361</pub-id></element-citation></ref><ref id="R45"><label>45.</label><element-citation publication-type="journal"><name name-style="western"><surname>Pecori Giraldi</surname><given-names>F</given-names></name><name name-style="western"><surname>Cassarino</surname><given-names>MF</given-names></name><name name-style="western"><surname>Sesta</surname><given-names>A</given-names></name><etal/><article-title>Silibinin, an Hsp90 inhibitor, on human ACTH-secreting adenomas.</article-title><source>Neuroendocrinology.</source><year>2023</year><volume>113</volume><fpage>606</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1159/000529710</pub-id><pub-id pub-id-type="pmid">36791678</pub-id><pub-id pub-id-type="pmcid">PMC10233703</pub-id></element-citation></ref><ref id="R46"><label>46.</label><element-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W-G</given-names></name><article-title>The roles of Histone Deacetylases and their inhibitors in cancer therapy.</article-title><source>Front Cell Dev Biol.</source><year>2020</year><volume>8</volume><fpage>576946</fpage><pub-id pub-id-type="doi">10.3389/fcell.2020.576946</pub-id><pub-id pub-id-type="pmid">33117804</pub-id><pub-id pub-id-type="pmcid">PMC7552186</pub-id></element-citation></ref><ref id="R47"><label>47.</label><element-citation publication-type="journal"><name name-style="western"><surname>Takayasu</surname><given-names>S</given-names></name><name name-style="western"><surname>Kageyama</surname><given-names>K</given-names></name><name name-style="western"><surname>Daimon</surname><given-names>M</given-names></name><article-title>Advances in molecular pathophysiology and targeted therapy for Cushing’s disease.</article-title><source>Cancers (Basel).</source><year>2023</year><volume>15</volume><fpage>496</fpage><pub-id pub-id-type="doi">10.3390/cancers15020496</pub-id><pub-id pub-id-type="pmid">36672445</pub-id><pub-id pub-id-type="pmcid">PMC9857185</pub-id></element-citation></ref><ref id="R48"><label>48.</label><element-citation publication-type="journal"><name name-style="western"><surname>Feldhaus</surname><given-names>AL</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>K</given-names></name><name name-style="western"><surname>Dutzar</surname><given-names>B</given-names></name><etal/><article-title>Ald1613, a novel long-acting monoclonal antibody to control ACTH-driven pharmacology.</article-title><source>Endocrinology.</source><year>2017</year><volume>158</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1210/en.2016-1455</pub-id><pub-id pub-id-type="pmid">27906551</pub-id></element-citation></ref><ref id="R49"><label>49.</label><element-citation publication-type="other"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://Clinicaltrials.Gov" ext-link-type="uri">Clinicaltrials.Gov</ext-link><article-title>A study to evaluate the safety and PK of CRN04894 for the treatment of Cushing’s syndrome.</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link><comment>identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05804669">NCT05804669</ext-link>. 2024. Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT05804669" ext-link-type="uri">https://clinicaltrials.gov/study/NCT05804669</ext-link><comment>(Date last accessed: 5 April 2024)</comment></element-citation></ref><ref id="R50"><label>50.</label><element-citation publication-type="journal"><name name-style="western"><surname>Fowler</surname><given-names>MA</given-names></name><name name-style="western"><surname>Kusnetzow</surname><given-names>AK</given-names></name><name name-style="western"><surname>Han</surname><given-names>S</given-names></name><etal/><article-title>Effects of Crn04894, a nonpeptide orally bioavailable ACTH antagonist, on corticosterone in rodent models of ACTH excess.</article-title><source>J Endocr Soc.</source><year>2021</year><volume>5</volume><fpage>A167</fpage><lpage>A167</lpage><pub-id pub-id-type="doi">10.1210/jendso/bvab048.337</pub-id></element-citation></ref><ref id="R51"><label>51.</label><element-citation publication-type="journal"><name name-style="western"><surname>Koumarianou</surname><given-names>A</given-names></name><name name-style="western"><surname>Kaltsas</surname><given-names>GA</given-names></name><name name-style="western"><surname>Chatzellis</surname><given-names>E</given-names></name><etal/><article-title>Immunotherapeutics at the spearhead: Current status in targeting neuroendocrine neoplasms.</article-title><source>Endocrine.</source><year>2021</year><volume>73</volume><fpage>232</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s12020-021-02639-8</pub-id><pub-id pub-id-type="pmid">33544352</pub-id></element-citation></ref><ref id="R52"><label>52.</label><element-citation publication-type="journal"><name name-style="western"><surname>Angelousi</surname><given-names>A</given-names></name><name name-style="western"><surname>Alexandraki</surname><given-names>K</given-names></name><name name-style="western"><surname>Tsoli</surname><given-names>M</given-names></name><etal/><article-title>Hypophysitis (including IgG4 and immunotherapy).</article-title><source>Neuroendocrinology.</source><year>2020</year><volume>110</volume><fpage>822</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1159/000506903</pub-id><pub-id pub-id-type="pmid">32126548</pub-id></element-citation></ref><ref id="R53"><label>53.</label><element-citation publication-type="journal"><name name-style="western"><surname>Dai</surname><given-names>C</given-names></name><name name-style="western"><surname>Liang</surname><given-names>S</given-names></name><name name-style="western"><surname>Sun</surname><given-names>B</given-names></name><name name-style="western"><surname>Kang</surname><given-names>J</given-names></name><article-title>The progress of immunotherapy in refractory pituitary adenomas and pituitary carcinomas.</article-title><source>Front Endocrinol (Lausanne).</source><year>2020</year><volume>11</volume><fpage>608422</fpage><pub-id pub-id-type="doi">10.3389/fendo.2020.608422</pub-id><pub-id pub-id-type="pmid">33362722</pub-id><pub-id pub-id-type="pmcid">PMC7761748</pub-id></element-citation></ref><ref id="R54"><label>54.</label><element-citation publication-type="journal"><name name-style="western"><surname>Duhamel</surname><given-names>C</given-names></name><name name-style="western"><surname>Ilie</surname><given-names>MD</given-names></name><name name-style="western"><surname>Salle</surname><given-names>H</given-names></name><etal/><article-title>Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: Two case reports and a review of the literature.</article-title><source>J Pers Med.</source><year>2020</year><volume>10</volume><fpage>88</fpage><pub-id pub-id-type="doi">10.3390/jpm10030088</pub-id><pub-id pub-id-type="pmid">32823651</pub-id><pub-id pub-id-type="pmcid">PMC7563495</pub-id></element-citation></ref><ref id="R55"><label>55.</label><element-citation publication-type="other"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link><article-title>Nivolumab and Ipilimumab in Treating Patients With Rare Tumors.</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link><comment>Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02834013">NCT02834013</ext-link> Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT02834013" ext-link-type="uri">https://clinicaltrials.gov/study/NCT02834013</ext-link><comment>(Date last accessed: 24 January 2024)</comment></element-citation></ref><ref id="R56"><label>56.</label><element-citation publication-type="other"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://Clinicaltrials.Gov" ext-link-type="uri">Clinicaltrials.Gov</ext-link><article-title>Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors.</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link><comment>identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04042753">NCT04042753</ext-link>. 2023. Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT04042753" ext-link-type="uri">https://clinicaltrials.gov/study/NCT04042753</ext-link><comment>(Date last accessed: 5 April 2024)</comment></element-citation></ref><ref id="R57"><label>57.</label><element-citation publication-type="journal"><name name-style="western"><surname>Fleseriu</surname><given-names>M</given-names></name><name name-style="western"><surname>Pivonello</surname><given-names>R</given-names></name><name name-style="western"><surname>Elenkova</surname><given-names>A</given-names></name><etal/><article-title>Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing’s syndrome (SONICS): A phase 3, multicentre, open-label, single-arm trial.</article-title><source>Lancet Diabetes Endocrinol.</source><year>2019</year><volume>7</volume><fpage>855</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(19)30313-4</pub-id><pub-id pub-id-type="pmid">31542384</pub-id></element-citation></ref><ref id="R58"><label>58.</label><element-citation publication-type="journal"><name name-style="western"><surname>Pivonello</surname><given-names>R</given-names></name><name name-style="western"><surname>Zacharieva</surname><given-names>S</given-names></name><name name-style="western"><surname>Elenkova</surname><given-names>A</given-names></name><etal/><article-title>Levoketoconazole in the treatment of patients with endogenous Cushing’s syndrome: A double-blind, placebo-controlled, randomized withdrawal study (LOGICS).</article-title><source>Pituitary.</source><year>2022</year><volume>25</volume><fpage>911</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1007/s11102-022-01263-7</pub-id><pub-id pub-id-type="pmid">36085339</pub-id><pub-id pub-id-type="pmcid">PMC9675660</pub-id></element-citation></ref><ref id="R59"><label>59.</label><element-citation publication-type="journal"><name name-style="western"><surname>Pivonello</surname><given-names>R</given-names></name><name name-style="western"><surname>Elenkova</surname><given-names>A</given-names></name><name name-style="western"><surname>Fleseriu</surname><given-names>M</given-names></name><etal/><article-title>Levoketoconazole in the treatment of patients with Cushing’s syndrome and diabetes mellitus: Results from the SONICS phase 3 study.</article-title><source>Front Endocrinol (Lausanne).</source><year>2021</year><volume>12</volume><fpage>595894</fpage><pub-id pub-id-type="doi">10.3389/fendo.2021.595894</pub-id><pub-id pub-id-type="pmid">33897615</pub-id><pub-id pub-id-type="pmcid">PMC8059833</pub-id></element-citation></ref><ref id="R60"><label>60.</label><element-citation publication-type="journal"><name name-style="western"><surname>Fleseriu</surname><given-names>M</given-names></name><name name-style="western"><surname>Auchus</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Greenman</surname><given-names>Y</given-names></name><etal/><article-title>Levoketoconazole treatment in endogenous Cushing's syndrome: Extended evaluation of clinical, biochemical, and radiologic outcomes.</article-title><source>Eur J Endocrinol.</source><year>2022</year><volume>187</volume><fpage>859</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1530/EJE-22-0506</pub-id><pub-id pub-id-type="pmid">36251618</pub-id><pub-id pub-id-type="pmcid">PMC9716395</pub-id></element-citation></ref><ref id="R61"><label>61.</label><element-citation publication-type="journal"><name name-style="western"><surname>Pivonello</surname><given-names>R</given-names></name><name name-style="western"><surname>Fleseriu</surname><given-names>M</given-names></name><name name-style="western"><surname>Newell-Price</surname><given-names>J</given-names></name><etal/><article-title>Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): A multicentre phase III study with a double-blind, randomised withdrawal phase.</article-title><source>Lancet Diabetes Endocrinol.</source><year>2020</year><volume>8</volume><fpage>748</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(20)30240-0</pub-id><pub-id pub-id-type="pmid">32730798</pub-id></element-citation></ref><ref id="R62"><label>62.</label><element-citation publication-type="journal"><name name-style="western"><surname>Fleseriu</surname><given-names>M</given-names></name><name name-style="western"><surname>Newell-Price</surname><given-names>J</given-names></name><name name-style="western"><surname>Pivonello</surname><given-names>R</given-names></name><etal/><article-title>Long-term outcomes of osilodrostat in Cushing’s disease: LINC 3 study extension.</article-title><source>Eur J Endocrinol.</source><year>2022</year><volume>187</volume><fpage>531</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1530/EJE-22-0317</pub-id><pub-id pub-id-type="pmid">35980235</pub-id><pub-id pub-id-type="pmcid">PMC9513654</pub-id></element-citation></ref><ref id="R63"><label>63.</label><element-citation publication-type="journal"><name name-style="western"><surname>Gadelha</surname><given-names>M</given-names></name><name name-style="western"><surname>Bex</surname><given-names>M</given-names></name><name name-style="western"><surname>Feelders</surname><given-names>RA</given-names></name><etal/><article-title>Randomized trial of osilodrostat for the treatment of Cushing disease.</article-title><source>J Clin Endocrinol Metab.</source><year>2022</year><volume>107</volume><fpage>e2882</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1210/clinem/dgac178</pub-id><pub-id pub-id-type="pmid">35325149</pub-id><pub-id pub-id-type="pmcid">PMC9202723</pub-id></element-citation></ref><ref id="R64"><label>64.</label><element-citation publication-type="journal"><name name-style="western"><surname>Pivonello</surname><given-names>R</given-names></name><name name-style="western"><surname>Simeoli</surname><given-names>C</given-names></name><name name-style="western"><surname>Di Paola</surname><given-names>N</given-names></name><name name-style="western"><surname>Colao</surname><given-names>A</given-names></name><article-title>Cushing’s disease: Adrenal steroidogenesis inhibitors.</article-title><source>Pituitary.</source><year>2022</year><volume>25</volume><fpage>726</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1007/s11102-022-01262-8</pub-id><pub-id pub-id-type="pmid">36036308</pub-id><pub-id pub-id-type="pmcid">PMC9587932</pub-id></element-citation></ref><ref id="R65"><label>65.</label><element-citation publication-type="journal"><name name-style="western"><surname>Hunt</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Belanoff</surname><given-names>JK</given-names></name><name name-style="western"><surname>Walters</surname><given-names>I</given-names></name><etal/><article-title>Identification of the clinical candidate (R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl) Sulfonyl)-4,4A,5,6,7,8-Hexahydro-1H-Pyrazolo[3,4-G]Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone (Cort125134): A selective glucocorticoid receptor (GR) antagonist.</article-title><source>J Med Chem.</source><year>2017</year><volume>60</volume><fpage>3405</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b00162</pub-id><pub-id pub-id-type="pmid">28368581</pub-id></element-citation></ref><ref id="R66"><label>66.</label><element-citation publication-type="journal"><name name-style="western"><surname>Hunt</surname><given-names>H</given-names></name><name name-style="western"><surname>Donaldson</surname><given-names>K</given-names></name><name name-style="western"><surname>Strem</surname><given-names>M</given-names></name><etal/><article-title>Assessment of safety, tolerability, pharmacokinetics, and pharmacological effect of orally administered Cort125134: An adaptive, double-blind, randomized, placebo-controlled phase 1 clinical study.</article-title><source>Clin Pharmacol Drug Dev.</source><year>2018</year><volume>7</volume><fpage>408</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1002/cpdd.389</pub-id><pub-id pub-id-type="pmid">28967708</pub-id><pub-id pub-id-type="pmcid">PMC5947602</pub-id></element-citation></ref><ref id="R67"><label>67.</label><element-citation publication-type="journal"><name name-style="western"><surname>Pivonello</surname><given-names>R</given-names></name><name name-style="western"><surname>Bancos</surname><given-names>I</given-names></name><name name-style="western"><surname>Feelders</surname><given-names>RA</given-names></name><etal/><article-title>Relacorilant, a selective glucocorticoid receptor modulator, induces clinical improvements in patients with Cushing syndrome: Results from a prospective, open-l abel phase 2 study.</article-title><source>Front Endocrinol.</source><year>2021</year><volume>12</volume><fpage>662865</fpage><pub-id pub-id-type="doi">10.3389/fendo.2021.662865</pub-id><pub-id pub-id-type="pmcid">PMC8317576</pub-id><pub-id pub-id-type="pmid">34335465</pub-id></element-citation></ref><ref id="R68"><label>68.</label><element-citation publication-type="journal"><name name-style="western"><surname>Molitch</surname><given-names>ME</given-names></name><article-title>Glucocorticoid receptor blockers.</article-title><source>Pituitary.</source><year>2022</year><volume>25</volume><fpage>733</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1007/s11102-022-01227-x</pub-id><pub-id pub-id-type="pmid">35507245</pub-id></element-citation></ref><ref id="R69"><label>69.</label><element-citation publication-type="other"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://Clinicaltrials.Gov" ext-link-type="uri">Clinicaltrials.Gov</ext-link><article-title>A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome (GRACE).</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link><comment>Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03697109">NCT03697109</ext-link>. 2024. Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT03697109" ext-link-type="uri">https://clinicaltrials.gov/study/NCT03697109</ext-link><comment>(Date last accessed: 5 April 2024)</comment></element-citation></ref><ref id="R70"><label>70.</label><element-citation publication-type="other"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://Clinicaltrials.Gov" ext-link-type="uri">Clinicaltrials.Gov</ext-link><article-title>Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas (GRADIENT).</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link><comment>Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04308590">NCT04308590</ext-link>. 2024. Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://classic.clinicaltrials.gov/ct2/show/NCT04308590" ext-link-type="uri">https://classic.clinicaltrials.gov/ct2/show/NCT04308590</ext-link><comment>(Date last accessed: 5 April 2024)</comment></element-citation></ref><ref id="R71"><label>71.</label><element-citation publication-type="journal"><name name-style="western"><surname>Pivonello</surname><given-names>R</given-names></name><name name-style="western"><surname>Munster</surname><given-names>PN</given-names></name><name name-style="western"><surname>Terzolo</surname><given-names>M</given-names></name><etal/><article-title>Glucocorticoid receptor antagonism upregulates somatostatin receptor subtype 2 expression in ACTH-producing neuroendocrine tumors: New insight based on the selective glucocorticoid receptor modulator relacorilant.</article-title><source>Front Endocrinol. ;12 n.d.</source><pub-id pub-id-type="doi">10.3389/fendo.2021.793262</pub-id><pub-id pub-id-type="pmcid">PMC8764187</pub-id><pub-id pub-id-type="pmid">35058882</pub-id></element-citation></ref><ref id="R72"><label>72.</label><element-citation publication-type="journal"><name name-style="western"><surname>Mallick</surname><given-names>S</given-names></name><name name-style="western"><surname>Chakrabarti</surname><given-names>J</given-names></name><name name-style="western"><surname>Eschbacher</surname><given-names>J</given-names></name><etal/><article-title>Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators.</article-title><source>Transl Res.</source><year>2023</year><volume>256</volume><fpage>56</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.trsl.2023.01.002</pub-id><pub-id pub-id-type="pmid">36640905</pub-id><pub-id pub-id-type="pmcid">PMC11345864</pub-id></element-citation></ref><ref id="R73"><label>73.</label><element-citation publication-type="journal"><name name-style="western"><surname>Braun</surname><given-names>LT</given-names></name><name name-style="western"><surname>Rubinstein</surname><given-names>G</given-names></name><name name-style="western"><surname>Zopp</surname><given-names>S</given-names></name><etal/><article-title>Recurrence after pituitary surgery in adult Cushing's disease: A systematic review on diagnosis and treatment.</article-title><source>Endocrine.</source><year>2020</year><volume>70</volume><fpage>218</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1007/s12020-020-02432-z</pub-id><pub-id pub-id-type="pmid">32743767</pub-id><pub-id pub-id-type="pmcid">PMC7396205</pub-id></element-citation></ref><ref id="R74"><label>74.</label><element-citation publication-type="journal"><name name-style="western"><surname>Capatina</surname><given-names>C</given-names></name><name name-style="western"><surname>Hinojosa-Amaya</surname><given-names>JM</given-names></name><name name-style="western"><surname>Poiana</surname><given-names>C</given-names></name><name name-style="western"><surname>Fleseriu</surname><given-names>M</given-names></name><article-title>Management of patients with persistent or recurrent Cushing’s disease after initial pituitary surgery.</article-title><source>Expert Rev Endocrinol Metab.</source><year>2020</year><volume>15</volume><fpage>321</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1080/17446651.2020.1802243</pub-id><pub-id pub-id-type="pmid">32813595</pub-id></element-citation></ref><ref id="R75"><label>75.</label><element-citation publication-type="journal"><name name-style="western"><surname>Neou</surname><given-names>M</given-names></name><name name-style="western"><surname>Villa</surname><given-names>C</given-names></name><name name-style="western"><surname>Armignacco</surname><given-names>R</given-names></name><etal/><article-title>Pangenomic classification of pituitary neuroendocrine tumors.</article-title><source>Cancer Cell.</source><year>2020</year><volume>37</volume><fpage>123</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2019.11.002</pub-id><pub-id pub-id-type="pmid">31883967</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>